Holzer Health System

The 340B Drug Pricing Program was created in 1992 to help eligible healthcare providers, such as hospitals and clinics serving low-income and underserved populations, purchase prescription medications at a discounted price. The program has been a critical source of support for these provider networks, helping to expand access to affordable healthcare for their patients. However, in recent years, there has been growing debate over the future of the 340B program due to drug manufacture concerns regarding the value to hospitals and providers in unsupported areas.

One of the main challenges facing the 340B program is a lack of clarity around its purpose and scope. Some critics against the 340B program argue that the program has become too broad allowing it to be used by some hospitals to generate profits rather than to provide care to vulnerable patients. Others in support of the 340B program argue that the program is essential to maintaining access to care for underserved populations and that any changes to it could have serious consequences for patients and underserved communities.

Hospital pharmacies have played an important role in the 340B program, as they are responsible for the purchasing and dispensing of 340B discounted drugs to eligible patients by in-house and contract pharmacies. Manufacture lobbyist have been expressing concern that hospital pharmacies are not using the program as intended and may be profiting from the discounts without utilizing the expense for expanded access for patients. In response, some policymakers have proposed changes to the program that would limit the role of hospital pharmacies to utilize contract pharmacy networks and increase oversight to ensure that the program is being used appropriately.

“By working together to address the challenges facing the program and embracing new models of care and innovation, healthcare providers and patient advocates can help to ensure that the 340B program continues to serve its intended purpose of expanding access to affordable health care for underserved populations.”

Despite these challenges, there are also reasons to be optimistic about the future of the 340B program and hospital pharmacies. Most healthcare providers and patient advocates believe that the program is essential to maintaining access to care for underserved populations and that any changes to it must be carefully weighed to ensure that patients are not harmed by reduction in services. Additionally, there are efforts underway to increase transparency and accountability in the program, which could help to address some of the concerns around its use.  The expansion of the 340B ESP program has created a window of transparency for Manufactures to see true utilization of their discounted products to hospitals and where care benefits are being generated.  The challenge will be keeping Third Party Payors from attempting to manipulate this data to enhance their profits at the expense of patient access in underserved areas.

In terms of acute hospitals and entity owned pharmacies specifically, there are also opportunities for growth and innovation. For example, some hospitals are exploring new models of care that involve closer collaboration between pharmacists and other healthcare providers, which could help to improve patient outcomes and reduce costs. Additionally, advances in technology and data analytics are helping hospital pharmacies to better track drug utilization and identify opportunities for cost savings and quality improvement. Overall, the future of the 340B program is uncertain, but there are reasons to be hopeful. By working together to address the challenges facing the program and embracing new models of care and innovation, healthcare providers and patient advocates can help to ensure that the 340B program continues to serve its intended purpose of expanding access to affordable health care for underserved populations.